Title: Yakup-- LegoChem will become an 'R&D-focused pharmaceutical company' through the acquisition of Khanmed

Publication: Yakup/ Kwon Gu Lee

Date: 1 October 2015

Summary

• LegoChem decided to acquire Khanmed, a medicine sales company. LegoChem's plan was to acquire 20% of Khanmed's stock and acquire in the future. Through this contract, they moved up the plan to merge.

• CEO Yong Zu Kim said, "Our vision is to become a research-based pharmaceutical company that has the function to research, produce, sell, and market. The acquisition of Khanmed has set a solid foundation toward our vision."

• Through the acquisition, LegoChem will be using a new strategic model that combines venture business, pharmaceutical company, and the clinic.

To view the full article (in Korean), click here ▶

About LegoChem Biosciences

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).